Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Bloomberg's Madison Muller also discusses the implications for Novo Nordisk. Video Transcript 00:00 Speaker A Madison, talk to us about Eli Lilly because, to Danny's point, they're one of the few bright spots at least this morning. I mean, talk to us about how much their expansion into pills and other powerful weight loss drugs will drive their future growth. 00:10 Madison Yeah, exactly. Thank you guys so much for having me. I mean, it's another amazing quarter for Lily.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。